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Summary
The VHL tumor suppressor protein (pVHL) is part of an E3 ubiquitin ligase that targets HIF for
destruction. pVHL-defective renal carcinoma cells exhibit increased NF-κB activity but the
mechanism is unclear. NF-κB affects tumorigenesis and therapeutic resistance in some settings. We
found that pVHL associates with the NF-κB agonist Card9 but does not target Card9 for destruction.
Instead, pVHL serves as an adaptor that promotes the phosphorylation of the Card9 C-terminus by
CK2. Elimination of these sites markedly enhanced Card9's ability to activate NF-κB in VHL+/+
cells and Card9 siRNA normalized NF-κB activity in VHL−/− cells and restored their sensitivity to
cytokine-induced apoptosis. Furthermore, downregulation of Card9 in VHL−/− cancer cells reduced
their tumorigenic potential. Therefore pVHL can serve as an adaptor for both an ubiquitin conjugating
enzyme and for a kinase. The latter activity, which promotes Card9 phosphorylation, links pVHL to
control of NF-κB activity and tumorigenesis.
Inactivation of the VHL tumor suppressor gene plays a role in the pathogenesis of clear cell
renal carcinomas, hemangioblastomas, and pheochromocytomas (Kim and Kaelin, 2004). The
best understood function of the VHL tumor suppressor protein (pVHL) relates to its role as the
substrate recognition unit of an E3 ubiquitin ligase complex that targets the alpha subunits of
the heterodimeric transcription factor HIF (hypoxia-inducible factor) for destruction (Kaelin,
2007; Schofield and Ratcliffe, 2004). The interaction between pVHL and HIFα requires that
HIFα be hydroxylated on either of two prolyl residues by members of the EglN family (also
called PHDs or HPHs), which are oxygen-dependent enzymes that have evolved to respond to
changes in oxygen over a physiologically relevant range in an intracellular milieu (Kaelin,
2007; Schofield and Ratcliffe, 2004). Increased HIF activity as a result of VHL inactivation
contributes to renal carcinoma growth and probably plays a role in the development of
hemangioblastomas (Kondo et al., 2003; Kondo et al., 2002; Maranchie et al., 2002; Raval et
al., 2005; Zimmer et al., 2004).
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Several lines of evidence, however, suggest that pVHL has functions in addition to regulating
HIF. First, there are genotype-phenotype correlations with respect to site-specific tumor risk
among individuals who carry a mutant VHL allele in their germline (VHL disease) (Kaelin,
2002). For example, some VHL alleles cause familial pheochromocytoma without an increased
risk of hemangioblastoma and renal cell carcinoma. The products of these alleles appear to be
normal with respect to HIF regulation but instead are compromised with respect to another
pVHL target, aPKC (Clifford et al., 2001; Hoffman et al., 2001; Lee et al., 2005). Increased
aPKC activity protects pheochromocytoma cells from apoptosis after growth factor withdrawal
(Lee et al., 2005). It is probable that the other genotype-phenotype correlations in VHL disease
are likewise manifestations of the degree to which different pVHL functions are quantitatively
or qualitatively altered.
Second, chronic HIF activation does not appear to be sufficient for tumor development.
Individuals who are chronically hypoxemic, such as occurs with life at high altitude or with
various medical conditions, develop secondary polycythemia because of HIF accumulation
and increased production of HIF-responsive gene products such as Erythropoietin (Golde and
Hocking, 1981). However, the risk of developing the tumors seen in VHL disease is not
conspicuously increased in these individuals. Similarly, individuals who are homozygous for
a VHL allele that is hypomorphic with respect to HIF, or who carry a defective EglN1 allele,
develop polycythemia but are not remarkably tumor prone (Gordeuk et al., 2004; Percy et al.,
2006). Tumors are also not, so far, a feature of mice engineered to produce stabilized versions
of HIFα (Kim et al., 2006)(WYK and WGK-unpublished data). These mice instead develop
increased angiogenesis and, in some cases, polycythemia.
Finally, pVHL has been reported to bind to a dozen different proteins, has been found in
multiple cellular compartments, and has been implicated in diverse cellular processes including
cell division, apoptosis, differentiation, and control of extracellular matrix formation (Czyzyk-
Krzeska and Meller, 2004; Kaelin, 2007). While some of these biological functions might relate
to HIF, others, based on genetic experiments in human cells and model organisms, involve
HIF-independent pVHL functions (Bishop et al., 2004; Calzada et al., 2006).
Clear cell renal carcinoma is the most common form of kidney cancer. Most of these tumors
harbor biallelic VHL mutations or fail to produce VHL mRNA due to VHL promoter
hypermethylation (Kim and Kaelin, 2004). Kidney cancers are difficult to treat medically and
frequently exhibit increased NF-κB activity, which can promote resistance to chemotherapy
or cytokines. Several studies have reported increased NF-κB activity in pVHL-defective renal
carcinoma cells but how pVHL loss promotes NF-κB activity is unclear (An et al., 2005; An
and Rettig, 2005; Oya et al., 2001; Oya et al., 2003; Qi and Ohh, 2003). Here we report that
pVHL, bound to Casein Kinase 2, promotes the inhibitory phosphorylation of the NF-κB
agonist Card9. Failure to phosphorylate Card9, which is known to interact with Bcl10 upstream
of NF-κB (Bertin et al., 2000; Gross et al., 2006), leads to increased NF-κB activity and
decreased apoptosis. Elimination of Card9 in pVHL-defective cells normalized NF-κB activity
and restored sensitivity to a proapoptotic cytokine. Downregulation of Card9 in VHL−/− cancer
cells retarded tumor growth. Therefore Card9 links pVHL to NF-κB biology and control of
tumor growth.
Results
pVHL associates with Card9
To search for additional pVHL substrates we purified pVHL-associated proteins from PC12
pheochromocytoma cells that were engineered to produce HA-pVHL and treated with the
proteasomal inhibitor MG132 (Figure 1A). Cell extracts were first fractionated by FPLC using
a DEAE column. Fractions that were enriched for pVHL and the known pVHL substrate
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HIF1α, as determined by pVHL far western blotting (Figure 1B), were pooled, concentrated
by ammonium sulfate precipitation, and subjected to alternating positive and negative affinity
purification steps using anti-HA, control, and anti-pVHL antibodies. After the last step bound
proteins were resolved by SDS-PAGE and analyzed by mass-spectrometry. Among the
peptides identified, eight peptides from the NF-κB agonist Card9 were recovered (Figure 1C).
Since we isolated multiple Card9 peptides and VHL-deficient cells display increased NF-κB
activity (An et al., 2005; An and Rettig, 2005; Qi and Ohh, 2003), we pursued the interaction
of pVHL with Card9 further.
In vitro translated Myc-Card9 bound to bacterially produced GST-pVHL (complexed with
elongin B and elongin C) in vitro (Figure 1D). This interaction was specifically blocked by a
hydroxylated HIF1α peptide that docks with the pVHL β-domain (Figure 1D) (Hon et al.,
2002; Min et al., 2002), suggesting that the pVHL β-domain is also important for binding to
Card9. HA-pVHL and Myc-Card9 also bound to one another in cotransfection assays with
HeLa cells (Figure 1E). Interestingly, Myc-Card9 migrated as a doublet in these assays and
the lower (or ‘bottom’) band consistently displayed a higher affinity for HA-pVHL than the
upper (or ‘top’) band. Consistent with the peptide competition assays, mutational analysis
revealed that pVHL beta domain residues 92−121, which are critical for recognition of
hydroxylated HIF1α, contribute to Card9 binding (Figure 1F). To ask if pVHL can bind to
Card9 under endogenous conditions, U937 VHL+/+ leukemia cells were metabolically labeled
with 35S and immunoprecipitated with control, anti-pVHL, or anti-Card9 antibodies. After
extensive washing the bound proteins were eluted by boiling in SDS and, after dilution of the
SDS, reimmunoprecipitated with the same or a different antibody. The initial anti-pVHL
immunoprecipitate contained a protein doublet of the expected molecular weight for Card9
that was recognized by an anti-Card9 antibody, but not a control antibody, in the second
immunoprecipitation. Moreover, this doublet comigrated with the doublet captured when
proteins released from the initial anti-Card9 immunoprecipitation reaction were
reimmunoprecipitated with the same anti-Card9 antibody under denaturing conditions (Figure
1G and data not shown). This suggests that pVHL can interact with Card9 under physiological
conditions. Note that Fig 1G cannot be directly compared to Fig 1E because different
electrophoretic conditions were used (15% vs. 10% polyacrylamide, respectively) and because
Fig 1G, in contrast to Fig 1E, depicts only newly synthesized Card9.
pVHL promotes the phosphorylation of the Card9 C-terminus by CK2
In pilot experiments we determined that Card9 abundance was not altered in VHL+/+ cells
treated with proteasomal inhibitors or hydroxylase inhibitors, in contrast to the canonical pVHL
substrate HIFα (data not shown). Instead, we noted that the Card9 top band was virtually absent
in VHL−/− pRC3 cells (Figure 2A). Similar results were observed in isogenic A498 renal
carcinoma cells that do or do not contain wild-type pVHL (Figure S1). WT8 cells and pRC3
cells are 786-O VHL−/− renal carcinoma cell subclones that were stably transfected with a
plasmid encoding wild-type pVHL or with the backbone vector, respectively (Iliopoulos et al.,
1995). The top band and bottom band isolated from cells that contain wild-type pVHL (Hep3B
and WT8) collapsed into a faster migrating form when phosphatase treated, suggesting that
pVHL promotes the (hyper)phosphorylation of Card9 (Figure 2B).
To pursue this idea further, we transiently transfected cells that do or do not contain wild-type
pVHL with a plasmid encoding Myc-Card9. Under these experimental conditions only the top
band was detected in cells containing wild-type pVHL (WT8 and HeLa cells) while both the
top and bottom bands were detected in the VHL−/− pRC3 cells (Figure 2C). The appearance
of an exogenous top band of Card9 in VHL−/− cells, in contrast to the behavior of endogenous
Card9, might be due to the higher concentrations of Card9 achieved after transient transfection.
For example, these conditions might promote the interaction of Card9 with the relevant kinase
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(s) and hence partially obviate the need for an adaptor (see below). Nonetheless, the Card9
bottom band reappeared in HeLa cells producing Myc-tagged Card9 and treated with VHL
siRNA (Figure 2C and Figure S2). Conversely, incubation of dephosphorylated Myc-Card9
with a pVHL-containing cell extract led to the appearance of the top band in vitro, which
disappeared upon lambda phosphatase treatment (Figure 2D).
These results indicated that pVHL promotes Card9 phosphorylation. In parallel we discovered
that pVHL associates with a kinase that can phosphorylate Card9 in vitro (Figure 3A). pVHL
was recently reported to be a CK2 substrate (Lolkema et al., 2005). We independently
discovered that pVHL is a CK2 substrate (data not shown), which led us to ask if CK2 binds
to pVHL. We found that CK2 and pVHL can be coimmunoprecipitated (Figure 3B), raising
the possibility that pVHL acts as an adaptor to promote the phosphorylation of Card9 by CK2.
In support of this, pVHL enhanced the binding of Card9 and CK2 in vivo (Figure 3C).
The Card9 C-terminus contains multiple serine and threonine residues that resemble CK2
phosphorylation sites. Mass spectrometry analysis of Myc-Card9 recovered from HeLa cells
revealed that these sites, including T531 and T533, were phosphorylated in vivo (Figure S3).
These sites were also phosphorylated by CK2 in vitro, as determined by mass spectrometry,
which coincided with the appearance of the Card9 top band (Figure 3D). Conversely, the top
band/bottom band ratio was markedly decreased in HeLa cells transfected to produce epitope-
tagged Card9 and treated with siRNA directed against the CK2 catalytic (CK2α) or regulatory
(CK2β) subunits (Figure 3E). In addition, the top band of endogenous Card9 in Hep3B cells
was eliminated with the CK2 inhibitor TBB but not a Cdk inhibitor (Figure 3F).
To study this further, we generated a polyclonal antibody that recognizes a Card9 peptide
phosphorylated on T531 and T533 (Figure S4A). This antibody preferentially recognized the
Card9 top band and did not react with exogenous or endogenous Card9 following phosphatase
treatment (Figure 3G and Figure S4B). Using this reagent, we confirmed that anti-pVHL
immunoprecipitates direct the phosphorylation of these two residues in vitro (Figure 3H) and
that this reaction is specifically inhibited by TBB (Figure S4C). Moreover, Card9
phosphorylation was diminished following somatic VHL inactivation in vivo (Figure 3I).
Phosphorylation of the Card9 C-terminus Inhibits Its Ability to Activate NF-κB
To decipher the functional relevance of Card9 phosphorylation by CK2 we created C-terminal
Card9 truncation and missense mutants. In pilot experiments, we confirmed that Card9 is an
NF-κB agonist (Figure 4A). Deletion of the Card9 C-terminus, and hence all of the Card9 C-
terminal CK2 sites, eliminated the top band, as expected (Figure 4B). Moreover, deletion of
the Card9 C-terminus markedly increased its ability to enhance NF-κB activity (Figure 4B)
(note different y-axes in Figure 4A and Figure 4B). Elimination of 4 C-terminal CK2 sites
within Card9, alone or in combination, by alanine substitutions also increased reporter activity
and replacement of all 4 sites with alanines markedly decreased top band formation (Figure
4C). Likewise, the Card9 phosphosite mutants were more potent than wild-type Card9 with
respect to the induction of the NF-κB target gene TNFα (Figure 4D) and NF-κB DNA-binding
activity (Figure S5A). Consistent with this latter observation, NF-κB DNA-binding activity
was also increased in cells treated with a CK2 inhibitor (Figure S5B). These results indicate
that phosphorylation of the Card9 C-terminus impairs its ability to activate NF-κB.
Increased NF-κB activity in VHL−/− cells requires Card9
In keeping with earlier studies (An et al., 2005; An and Rettig, 2005; Qi and Ohh, 2003), we
observed that the activity of artificial and naturally occurring NF-κB responsive promoters was
increased in VHL−/− renal carcinoma cells relative to their wild-type pVHL counterparts
(Figure 5A and B). In keeping with this, the induction of the endogenous NF-κB targets
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TNFα and IκBα by the NF-κB agonist TNFα was much more pronounced in VHL−/− cells
compared to their wild-type counterparts (Figure 5C and D). The changes in IκBα mRNA were
mirrored by changes in the accumulation of IκBα protein (Figure S6), which again supports
the earlier conclusion of others that endogenous NF-κB activity is enhanced in VHL−/− cells.
Likewise, a number of NF-κB target genes were transcriptionally activated after conditional
inactivation of VHL in VHL flox/flox mice (Haase et al., 2001) that ubiquitously express a Cre-
ER fusion protein (Vooijs et al., 2001) (Table 1). These effects were seen in liver (Table 1) but
not spleen (data not shown), suggesting that regulation of Card9 and NF-κB by pVHL is tissue-
specific. Similarly, endogenous NF-kB targets were activated in livers of VHL flox/flox mice
expressing Cre recombinase under the control of the Albumin promoter (Haase et al., 2001;
Kim et al., 2006) (Figure S7).
The increased NF-κB activity observed in VHL−/− renal carcinoma cells is, at least partly, due
to Card9 because it was effectively neutralized with several independent Card9 siRNAs/
shRNA (Figure 5C-E and Figures S8 and S9). The behavior of the Card9 shRNA in these assays
was similar to that of an siRNA directed against Bcl10, which together with its partner Card9,
stimulates NF-κB activity (Figure S10). Similarly, VHL siRNA increased NF-κB activity in
VHL+/+ Hep3B cells, which was partially blocked by coadministration of Card9 siRNA
(Figure 5F). This suggests that Card9 acts downstream or parallel of pVHL and supports the
idea that increased NF-κB activity in VHL−/− renal carcinoma cells reflects a failure to properly
phosphorylate Card9.
Increased NF-κB activity in VHL−/− renal carcinoma cells is not due to HIF dysregulation
We confirmed the recent finding that HIF2α, at least when artificially overproduced in some
cell types, can also activate NF-κB (data not shown) (An and Rettig, 2005). This led us to ask
whether NF-κB activation after pVHL loss was primarily due to Card9, HIFα, or both. 786-O
cells produce HIF2α but not HIF1α (Maxwell et al., 1999). We identified 3 different HIF2α
siRNAs that reduced HIF transcriptional activity in VHL−/− pRC3 cells to the levels seen in
pVHL-proficient WT8 cells (Figure 6A and data not shown). These HIF2α siRNAs did not,
however, diminish NF-κB activity (Figure 6B). ARNT1 is the major DNA-binding partner for
HIFα. As expected, HIF transcriptional activity was markedly increased in ARNT1+/+ mouse
hepatoma cells (Hoffman et al., 1991), but not in their ARNT1−/− counterparts, by VHL siRNA
(Figure 6C). In stark contrast, however, NF-κB activation by VHL siRNA was ARNT1-
independent (Figure 6D). Overproduction of a stabilized version of HIF2α (Kondo et al.,
2003) in mouse hepatoma cells activated a HIF-responsive promoter (Figure 6E) but did not
activate NF-κB, regardless of ARNT1 status (Figure 6F), which argues against the possibility
that NF-κB activation by VHL siRNA in these cells reflects an ARNT1-independent function
of HIF2α. Finally, we have not observed NF-κB activation in cells in which HIF is activated
by hypoxia or hypoxia mimetics (data not shown). Collectively, these results suggest that
pVHL inhibits NF-κB activity primarily by promoting the inhibitory phosphorylation of Card9
by CK2.
Deregulation of Card9 in VHL−/− Tumor Cells Leads to Cytokine Resistance and Enhanced
Tumorigenesis
Enhanced NF-κB activity protects against TNFα–induced cell death (Beg and Baltimore,
1996; Van Antwerp et al., 1996; Wang et al., 1996) and VHL−/− renal carcinoma cells are
relatively resistant to this cytokine (Caldwell et al., 2002). Stable downregulation of Card9 in
VHL−/− renal carcinoma cells with a Card9 shRNA restored their sensitivity to the proapoptotic
cytokine TNFα to levels seen in cells producing wild-type pVHL (Figure 7A). TNFα can, itself,
induce NF-κB. In order to investigate basal levels of NF-κB, we blocked the induction with
cycloheximide, as done by others before (Brummelkamp et al., 2003) (Wang et al., 1996). The
effect of the Card9 shRNA was specifically due to Card9 downregulation because it was largely
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reversed by coexpression of a Card9 cDNA bearing silent mutations that destroy the shRNA
recognition sequence without altering the Card9 protein sequence (Figure S11).
Next we performed orthotopic xenograft assays with VHL−/− kidney cancer cells expressing
either a scrambled shRNA or Card9 shRNA. Downregulation of Card9 substantially decreased
tumor growth (Figure 7B). The Card9 rescue cDNA described above nullified the effect of the
Card9 shRNA, indicating that the observed suppression of tumor formation was due
specifically to downregulation of Card9 and not an off-target effect (Figure 7C and D).
Discussion
We found that pVHL associates with the NF-κB agonist Card9, which is reported to act in
concert with Bcl10 upstream of NF-κB (Bertin et al., 2000; Gross et al., 2006). pVHL does
not direct the destruction of Card9. Instead pVHL facilitates the phosphorylation of Card9 by
CK2 on C-terminal residues that regulate Card9's ability to activate NF-κB. Card9 mutants
lacking these phosphorylation sites are NF-κB superagonists while elimination of Card9 in
VHL−/− renal carcinoma cells normalizes NF-κB activity and promotes apoptosis and
suppresses tumorigenesis. In contrast, deregulation of HIF does not, based on our genetic
experiments, appear to play a prominent role in promoting NF-κB activity when pVHL function
is compromised.
Our biochemical studies suggest that pVHL, bound to CK2, brings CK2 into proximity with
Card9 and thereby increases the local concentration of the substrate. Therefore pVHL can serve
as an adaptor for a kinase, CK2, as well as for the ubiquitin conjugating machinery that directs
the polyubiquitination of HIFα subunits (Figure 7E). Phosphorylation of the Card9 C-terminus
by CK2 might promote an inhibitory intra or intermolecular interaction or prevent the binding
of Card9 to an accessory protein required for its activity. In this regard, we have obtained
preliminary data that Card9 can interact with NEMO (also called IKKγ)(data not shown), which
might conceivably play a role here.
We observed decreased Card9 phosphorylation, and increased NF-κB activity, in mouse livers
after VHL inactivation, indicating that regulation of Card9 and NF-κB by pVHL occurs under
physiological conditions. To date the role of Card9 in NF-κB activation has been most clearly
documented during the myeloid immune response to particular infections (Colonna, 2007).
Clearly it will be important to determine the physiological and pathological signals that govern
the interaction of pVHL and Card9.
VHL mutations play a causal role in renal carcinomas, which are notoriously resistant to
chemotherapy, radiotherapy, and proapoptotic cytokines. Increased NF-κB activity, which has
been documented in renal carcinomas before (Oya et al., 2001; Oya et al., 2003), is likely to
play a role here (Karin et al., 2002; Nakanishi and Toi, 2005). Indeed, there is already preclinical
evidence that suppression of NF-κB in renal carcinomas with interferon alpha, which is widely
used in the treatment of this disease, can increase their sensitivity to chemotherapeutic agents
or other cytokines (Bukowski, 2000; Steiner et al., 2001). Further elucidation of Card9
regulation and function might reveal additional opportunities to manipulate NF-κB activity in
tumor cells.
All renal carcinoma-associated missense VHL mutants are defective for the regulation of HIF
but some preserve the ability to regulate Card9 (data not shown). This is consistent with HIF
playing a dominant role in VHL−/− renal tumors. Nonetheless, many of the VHL mutations
found in renal carcinomas are deletion, truncation, or nonsense mutations that would
predictably eliminate pVHL function (Gnarra et al., 1996). Our data suggests that, in this
setting, deregulation of Card9 would confer a more aggressive phenotype and resistance to
therapy.
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A number of HIF-responsive genes implicated in renal carcinogenesis, including VEGF, cyclin
D1, and MMP2/9, are also NF-κB targets, suggesting that HIF and NF-κB might act
cooperatively (Karin et al., 2002; Nakanishi and Toi, 2005). Agents that inhibit HIF-responsive
growth factors such as VEGF have demonstrated activity in kidney cancer clinical trials (Kim
and Kaelin, 2004) and might now be rationally combined with agents that modulate NF-κB
function.
Experimental Procedures
Partial Purification of pVHL-associated Proteins
PC12 cells stably transfected to produce human HA-VHL (generated by Michael Hoffman)
were incubated overnight with 10μM MG132 and lysed in EBC buffer (50mM Tris·HCl,
[pH8.0], 120mM NaCl, 0.5% Nonidet [NP]-40). Approximately 1 gm of clarified cell extract
was resolved by FPLC using a DEAE sepharose column (Amersham-Pharmacia). Aliquots of
column fractions were farwestern blotted with recombinant pVHL, elongin B, elongin C
complexes as described before (Yang et al., 2004). Fractions enriched for pVHL and HIF1α
were pooled, precipitated with 60% ammonium sulfate (final conc.), resolubilized in ∼ 1 ml
of EBC, and dialyzed overnight against EBC to remove excess salt prior to
immunoprecipitation with ∼50 μl of protein A sepharose crosslinked to 12CA5 (∼1 μg/μl) for
∼5 hours at 4 °C. After 3 washes with NETN (20mM Tris·HCl, [pH8.0], 100mM NaCl, 1mM
EDTA, 0.5% NP-40) the bound proteins were eluted with 1 μg/μl HA peptide in PBS buffer.
The eluate (total volume ∼ 600 μl) was then precleared by incubation with ∼ 30 μl sepharose
cross-linked to control antibody for ∼5 hours at 4 °C. The supernatant was then
immunoprecipitated with anti-VHL antibody (IG32) sepharose for ∼5 hours at 4 °C. Bound
proteins were eluted by boiling in SDS, resolved by SDS-PAGE, and analyzed by Mass
spectrometry at Taplin Mass Spectrometry Center at Harvard Medical School.
Antibodies
Monoclonal anti-HA antibodies (12CA5 and cross-linked 3F10) were from Roche Applied
Science. Anti-Myc antibodies (9B11, 9E10) were from Cell Signaling Technology and Zymed
respectively. Monoclonal anti-pVHL (IG32) was described before (Kibel et al., 1995). For
preparative immunoprecipitation of HA-pVHL complexes 12CA5, 9E10, IG32 were
crosslinked to Protein A sepharose (Amersham Pharmacia) using dimethyl pimelimidate
(Sigma). Polyclonal Anti-Card9 antibody was from Prosci. Polyclonal anti-CK2α antibodies
(BL753, BL754) were from Bethyl Laboratories. Monoclonal anti-CK2β(6D5) and polyclonal
anti-HA (Y11) were from Santa Cruz Biotechnology. Monoclonal anti-Card9 (TJ24) was made
by the DFCI antibody core facility using mice that were immunized with GST-Card9 (1−200).
Polyclonal antibodies recognizing T531T533 Card9 phosphopeptide (524−536) was made by
Bethyl Laboratories.
Plasmids
A full length Card9 cDNA clone (NM_052813) was purchased from Origene. The open reading
frame was PCR amplified with primers that introduced a 5'BamHI site and 3'EcoRI site to
facilitate subcloning into a pcDNA3 plasmid (Invitrogen) that introduced an N-terminal Myc-
epitope tag. Truncation and point mutants were made similarly using PCR primers that
introduced the desired mutations. All Card9 plasmids were confirmed by DNA sequencing.
Plasmids encoding LMP1 and DN-IκBα were gifts from Eliott Kieff and Ballad Dean,
respectively. pcDNA3-HIF2α P405A; P531A was described before (Kondo et al., 2003).
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Card9 was immunoprecipitated from EBC cell extracts using polyclonal anti-Card9
(endogenous) or anti-Myc (exogenous) antibodies. Immunoprecipitates were washed 3 times
with NETN and once with lambda phosphatase or alkaline phosphatase buffer (provided by
the manufacturer). The residual wash buffer was aspirated and the sepharose was resuspended
in 100 μl of lambda or alkaline phosphatase buffer containing 400 units or 40 units of the
corresponding enzymes. After 1 hour incubation at 30 °C the sepharose was washed once with
NETN and bound Card9 was eluted by boiling in SDS-containing sample buffer. Alternatively,
the sepharose was washed once with CK2 kinase buffer (20mM Hepes·NaOH, [pH7.9], 20mM
MgCl2, 150mM NaCl) and the bound Card9 used as a substrate for in vitro kinase assays (see
below). To prepare soluble, dephosphorylated, Myc-Card9, the above procedure was
performed using a Catch and Release kit (Upstate Biotechnology) to immunoprecipitate Myc-
Card9 and lambda phosphatase. Dephosphorylated Myc-Card9 was eluted according to the
manufacturer's instructions.
Chemicals and Recombinant Enzymes
TPA, recombinant CK2, CK2 inhibitor 4, 5, 6, 7-Tetrabromobenzotriazole (TBB), and 3-
Amino-1H-pyrazolo[3.4-b]quinoxaline were from EMD-Calbiochem. Alkaline and Lambda
phosphatase was from New England Biolabs. TNFα was from R&D Systems.
siRNA
Cells grown in six-well plates were transfected with 200 nM siRNA (except for CK2 siRNA
used at 100 nM) using Lipofectamine2000 (for mixtures of plasmids and siRNA oligos) or
Oligofectamine (for siRNA alone). SiRNAs were purchased from Dharmacon unless otherwise
indicated. Sense strands were as follows: VHLC 5'GCCUGAGAAUUACAGGAGATT3', and
VHLD 5'AGACCUGGAGCGGCUGACACTT3', Card9−03
5'CUACGUAAGGACUCCAAGATT3', Card9−06
5'GGAGAAGGAGAUGUUCGAGTT3' (Ambion), and Card9−07
5'GGACUCCAAGAUGUACAAGTT3' (Ambion). HIF2A01
5'GACAAGGUCUGCAAAGGGUTT3', HIF2A02 5'GGAGACGGAGGUGUUCUAUTT3',
and HIF2A03 5'CAGCAUCUUUGAUAGCAGUTT3', Bcl10
5'GATGAAGTGCTGAAACTTAGA3'. SCR 5'GCGCGCUUUGUAGGAUUCGTT3' was
used as control. siRNA oligos against CK2α (sc-29918) and CK2β (sc-29916) were purchased
from Santa Cruz Biotechnology. Mouse VHL siRNA smart pool was purchased from
Dharmacon (M-004916−00).
Metabolic Labeling
To detect endogenous complexes ∼20 ml of U937 leukemic suspension cells (∼2 × 107 cells)
were starved in Cysteine and Methionine-free media for 1 hour and then labeled with 2mCi
[35S] Methionine for four hours (0.2 mCi/ml). The cells were lysed in 3ml EBC buffer, split
into 3 aliquots, and immunoprecipitated with control, pVHL or Card9 antibodies. The
immunoprecipitates, bound to sepharose, were washed four times with NETN, eluted by
boiling in 50 μl 2% SDS for 5 minutes, and transferred to a second tube to which was added
1 ml EBC buffer. Aliquots of the eluate were then reimmunoprecipitated with the indicated
antibodies (Figure 1G).
In vitro kinase assays
Hypotonic cell extracts—∼ 20 15cm plates of nearly confluent cells were washed once
with PBS and resuspended in 10 ml cold hypotonic lysis buffer (HEB) (20mM Tris·HCl,
[pH7.5], 5mM KCl, 1.5 mM MgCl2, 1mM dithiothreitol) by mechanical scraping. The cells
were disrupted using a dounce homogenizer with the ‘B’ pestle for 30 to 40 strokes on ice.
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Crude extract was centrifuged twice (once at 10,000 × g for 10 minutes and then at 10,000 ×
g for 30 minutes) to remove cell debris and nuclei. Aliquots were flash frozen and stored at
−80°C before use (∼3−5 mg/ml as determined by Bradford Assay). 81μl of cell lysate and
9μl of 10X Energy Regenerating System (ERS, 20mM Tris·HCl, [pH7.5], 10mM ATP, 10mM
magnesium acetate, 300mM creatine phosphate, 0.5mg/ml creating phosphokinase) was added
to 20 μl of protein A sepharose preloaded with dephosphorylated Myc-Card9 (see above) and
gently mixed on a platform shaker for two hours at 30°C (Figure 2D).
Recombinant CK2—500 units recombinant E. coli CK2 (α2β2) was added to the 20 μl of
protein A sepharose preloaded with dephosphorylated Myc-Card9 (see above) in 100μl CK2
kinase buffer with 4μM ATP and gently mixed on a platform shaker for mixed for two hours
at 30°C (Figure 3D).
Immunoprecipitates—WT8 and pRC3 cells (∼2 15cm plates each) were
immunoprecipitated with 20μl anti-HA 3F10 beads. The sepharose was washed 3 times with
NETN and once with CK2 buffer. The residual wash buffer was aspirated and the sepharose
was resuspended in 74μl CK2 kinase buffer to which was added 4μM ATP and 4 μl of soluble,
dephosphorylated, Myc-Card9 (see above). At various timepoints aliquots (sepharose and
solution) were boiled and resolved by SDS-PAGE (Figure 3H).
Alternatively, HeLa cells were transfected with plasmids encoding HA-VHL and/or Myc-
Card9, lysed in EBC buffer, and immunoprecipitated with 20μl anti-HA 3F10 beads. After 3
washes with NETN the residual wash buffer was aspirated and the sepharose was resuspended
in 100μl CK2 kinase buffer containing 10μCi [32P] ATP. After 2 hour incubation at 30°C with
gentle agitation bound proteins were eluted by incubation at 95°C in 1% SDS for 5 minutes.
The eluates were collected, diluted 10-fold, split to two fresh tubes, and immunoprecipitated
with anti-HA or anti-Myc. Phosphorylated proteins were resolved by SDS-PAGE and detected
by autoradiography (Figure 3A).
Luciferase Assays
Cells grown in six-well plates were transfected with an NF-κB firefly luciferase reporter
plasmid [3X-κB-Luc (a gift from Elliot Kieff) or IL-6 promoter (a gift of BCCM/LMBP
(Plaisance et al., 1997)) and a renilla luciferase control plasmid (pRL-CMV; Promega) using
Lipofectamine2000 (Invitrogen) according to the manufacturer's instructions. Twenty-four
hours later firefly luciferase activity was measured using the Dual Luciferase Assay System
and normalized to renilla luciferase activity. For experiments where siRNA was used the cells
were split 1:2 24 hours after transfection and analyzed 24 hours later.
TNFα Killing Curves
10,000 cells/well were plated in 96 well plates. The next day the cells were treated with 9 μg/
ml cycloheximide together with increasing amounts (0, 0.37, 1.1, 3.3 ng/ml) of TNFα. Twenty
hours later, the media was replaced with 100 μl 0.05% crystal violet in 20% Methanol. After
a 20 minute incubation the plates were gently rinsed with water and allowed to air dry. The
remaining dye was dissolved with 100 μl acetic acid:methanol (1:3) and measured based on
absorbance at 590 nm.
Real Time RT-PCR
Cell Lines—Total RNA was isolated using RNeasy mini kit with on-column DNase digestion
(Qiagen). First-strand cDNA was generated using StrataScript First-Stand Synthesis System
(Statagene). Real-time PCR was performed in triplicate using QuantiTect SYBR Green PCR
master mix (Qiagen) and the Mx3000P QPCR system (Stratagene). Primers for TNFα and
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Iκbα were purchased from Qiagen (Cat No. QT01079561 and QT00014266, respectively). All
values were normalized to the level of Actin mRNA abundance.
Tissues—Three week old mice of indicated genotypes were injected with 2 mg Tamoxifen
intraperitoneally weekly for 3 weeks. RNA was extracted using Trizol and chloroform followed
by RNeasy mini kit (Qiagen). 2 μg of RNA was used to generate the first strand cDNA using
a SuperArray kit (SuperArray Bioscience), which was analyzed by real-time RT-PCR using
the SuperArray's RT2 Profiler PCR Array Mouse NF-κB Signaling Pathway plates according
to the manufacturer's instructions.
Orthotopic xenograft tumor growth assays and bioluminescence
Mice were anesthetized with ketamine hydrochloride and Xyla-Ject. A 2 cm incision was made
along the middle of the mouse. After the kidney was exposed, 2×106 viable cells were injected
near the lower pole into the renal parenchyma. After both kidneys were injected, wounds were
closed with absorbable suture or autoclip (Becton Dickinson) and subsequent renal tumors
were monitored by palpation. The mice were sacrificed ∼15 weeks after injection. Tumor mass
was calculated by subtracting the mass of the normal kidneys from the mass of the injected
kidneys. Results are presented as mean ± standard error of the mean (SEM).
For bioluminescent detection and quantification of cancer cells noninvasively, mice were given
a single i.p. injection of a mixture of luciferin (50 mg/kg) ketamine (150 mg/kg) and xylazine
(12 mg/kg) in sterile PBS buffer. Fifteen minutes later, mice were placed in a light-tight
chamber equipped with a charge-coupled device IVIS imaging camera (Xenogen, Alameda,
CA). Photons were collected for a period of 1–60 s, and images were obtained by using LIVING
IMAGE 2.60.1 software (Xenogen) and quantified using IGOR Pro 4.09A image analysis
software (WaveMatrics, Lake Oswego, OR). The total photons from the right were divided
with the total photons from the left, and the number at week three was arbitrarily set as 1. The
relative ratios of tumor mass at other time points were derived by dividing the calculated
numbers with the above number at week three, and the results were presented as mean ±
standard error of the mean (SEM).
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Figure 1. pVHL binds to Card9
(A) Purification schema.
(B) Farwestern blot analysis of DEAE sepharose fractions using recombinant pVHL as probe,
which was detected with anti-pVHL antibody.
(C) Primary sequence of Card9. Peptides recovered by mass spectrometry are underlined. Dots
indicate potential CK2 sites.
(D) Autoradiogram of 35S-Card9 bound to GST-pVHL in the presence of hydroxylated (OH)
or non-hydroxylated (WT) HIF1α peptide. Input = 10% of Card9 used for binding reaction.
(E) Immunoblot (IB) analysis of HeLa cells transfected to produce HA-pVHL and Myc-Card9
and immunoprecipitated (IP) with anti-HA antibody.
(F) Immunoblot analysis as in (E) of HeLa cells transfected to produce Myc-Card9 and
indicated HA-pVHL mutants. FL= full-length.
(G) Autoradiogram of immunoprecipitates derived from metabolically labeled U937 cells.
After initial immunoprecipitation (‘First IP’) under native conditions bound proteins were
released under denaturing conditions and reimmunoprecipitated with the indicated antibodies.
The identity of the intense 50 kD band in the sequential anti-pVHL, anti-pVHL lane is not
known.
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Figure 2. pVHL promotes Card9 hyperphosphorylation
(A) Anti-Card9 immunoblot analysis of whole cell extracts (left) or anti-Card9
immunoprecipitates (right) prepared from 786-O VHL−/− subclones stably producing wild-
type pVHL (WT8) or transfected with empty vector (pRC3). (*)= background band.
(B) Anti-Card9 immunoblot analysis of anti-Card9 immunoprecipitates derived from the
indicated cells. Immunoprecipitates were treated with alkaline or lambda phosphatase in
vitro where indicated.
(C) Anti-Myc immunoblot analysis of the indicated cell lines transfected to produce Myc-
Card9. Transfection mix contained VHL or control (SCR) siRNA where indicated.
(D) Anti-Myc immunoblot analysis of anti-Myc immunoprecipitates prepared from HeLa cells
producing Myc-Card9. Immunoprecipitates were dephosphorylated in vitro and then incubated
with WT8 or pRC3 cytosolic extract in the absence (−) or presence (+) of an energy regenerating
system (ERS). Immunoprecipitates were retreated with lambda phosphatase where indicated
prior to SDS-PAGE.
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Figure 3. pVHL promotes the phosphorylation of the Card9 C-terminus by CK2
(A) Autoradiogram of proteins phosphorylated in vitro by anti-HA immunoprecipitates derived
from HeLa cells transfected with the indicated plasmids. In vitro kinase assays were performed
in the presence of 32P-γ-ATP using anti-HA immunoprecipitates that were immobilized on
Protein A sepharose. Bound proteins were released by boiling in SDS-containing buffer and,
after SDS dilution, recaptured with anti-HA or anti-Myc antibody.
(B and C) Immunoblot analysis with indicated antibodies of control or CK2α
immunoprecipitates derived from HeLa cells that were (+) or were not (−) transfected to
produce HA-pVHL. In (C) cells were also transfected to produce Myc-Card9.
(D) Coomassie stained gel of anti-Myc immunoprecipitates from HeLa cells transiently
transfected to produce Myc-Card9. Immunoprecipitated Myc-Card9 was dephosphorylated in
vitro with lambda phosphatase and then incubated with recombinant CK2, where indicated,
prior to SDS-PAGE. Also shown are Card9 residues phosphorylated by CK2 under these
conditions as determined by mass spectrometry.
(E) Immunoblot analysis with the indicated antibodies of HeLa cells producing Myc-Card9
and treated with siRNA.
(F) Immunoblot analysis of endogenous Card9 immunoprecipitated from Hep3B cells treated
with DMSO, CK2 inhibitor TBB (4, 20, 100 μM), or Cdk inhibitor 3-Amino-1H-pyrazolo[3.4-
b]quinoxaline (100 μM).
(G) Immunoblot analysis with the indicated antibodies of anti-Myc immunoprecipitates
derived from HeLa cells transiently transfected to produce Myc-Card9 and treated with lambda
phosphatase where indicated.
(H) Immunoblot analysis with the indicated antibodies of anti-HA immunoprecipitates
prepared from WT8 or pRC3 cells and incubated with Myc-Card9 in vitro (see methods).
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(I) Immunoblot analysis with the indicated antibodies of anti-Card9 immunoprecipitates of
mouse liver extracts prepared from VHL flox/flox mice or VHL flox/flox; Cre-ER mice. 2-
week old mice were treated with tamoxifen on day 1 and 3 and livers were harvested 1 week
later.
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Figure 4. Phosphorylation of the Card9 C-terminus by CK2 inhibits NF-κB activity
(A) Normalized luciferase values of 293T cells transfected with an NF-κB-responsive
luciferase reporter plasmid and plasmids encoding GFP, Card9, or an NF-κB antagonist (DN-
IκBα). Error bars = 1 std. dev.
(B and C) Normalized luciferase values and immunoblot of 293T cells transfected to produce
the indicated Card9 mutants along with an NF-κB responsive luciferase reporter. On a lighter
exposure the Card9 (1−476) top band/bottom band ratio resembled the other truncation mutants
(data not shown).
(D) TNFα mRNA levels, normalized to Actin mRNA, of 293T cells transfected to produce the
indicated Card9 mutants (measured by RT-PCR).
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Figure 5. Increased NF-κB activity in VHL−/− Renal Carcinoma Cells Requires Card9
(A and B) Normalized luciferase values of WT8 and pRC3 cells transfected with artificial (A)
or naturally-occurring (B) NF-κB -responsive reporter. IL-6 = Interleukin 6 promoter. Mut-
Luc = same reporter with NF-κB site mutated. In (A) cells were treated with the NF-κB agonists
TPA or transfected to produce the NF-κB agonist LMP1, where indicated. Error bars = 1 std.
dev.
(C and D) TNFα and IκBα mRNA levels, normalized to Actin mRNA, in indicated cell lines
stimulated with 10ng/ml TNFα for indicated time (measured by RT-PCR). EV = empty vector.
SCR = scrambled shRNA.
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(E and F) Normalized luciferase values of WT8 and pRC3 cells (E) and Hep3B (F) cells
transfected with NF-κB-responsive reporter in the presence of the indicated siRNAs. SCR =
scrambled siRNA.
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Figure 6. Increased NF-κB activity in VHL−/− Renal Carcinoma Cells is Not Due to HIF
Dysregulation
(A and B). Normalized Luciferase values of VHL −/− pRC3 renal carcinoma cells transfected
with a HIF responsive (A) or NF-κB-responsive (B) reporter in the presence of the indicated
siRNAs. Error bars = 1 std. dev.
(C-F). Normalized Luciferase values of mouse hepatoma cells (ARNT1+/+ or −/−) transfected
with HIF responsive (C and E) or NF-κB-responsive (D and F) reporter in the absence or
presence of a plasmid encoding stabilized HIF2α (P405A; P531A) (E and F) or the indicated
siRNAs (C and D).
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Figure 7. Deregulation of Card9 in VHL−/− Tumor Cells Leads to Cytokine Resistance and
Enhanced Tumorigenesis
(A) Viability of the indicated cell lines after exposure to TNFα. Error bars = 1 std. dev, (B)
Tumor weights ∼15 weeks after orthotopic implantation of pRC3 VHL renal carcinoma cells
infected with retroviruses expressing the indicated shRNA in nude mice. Number of tumors
analyzed is shown in parentheses. Error bars = one standard error. Error bars = 1 std. dev.
(C) Representative bioluminescent images of nude mice after orthotopic implantation of
luciferase-positive 786-O cells expressing a Card9 shRNA in the absence (left) or presence
(right) of a rescue retrovirus encoding an exogenous Card9 mRNA that escapes recognition
by the shRNA.
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(D) Quantification of data in (C) (right/left) from five mice. Error bars = one standard error.
(E) Model for Regulation of HIF and Card9 by pVHL. For simplicity pVHL is shown binding
directly to Card9. Whether pVHL binds directly to Card9, or requires an accessory protein, is
not known.
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Table 1
Induction of NF-κB targets in liver after VHL inactivation.
Gene Name GenBank Fold induction after Cre activation
VHL +/+ Cre-ER VHL F/F Cre-ER
Ccl2/Mcp-1 NM_011333 1.1 3.2
Fos NM_010234 0.4 7.2
Icam1 NM_010493 1.3 5.9
IL1r1 NM_008362 0.5 5.9
Jun NM_010591 0.6 4.2
Nalp12 XM_355971 1.1 15.1
Slc20a1 NM_015747 1.2 3.6
Tgfbr2 NM_009371 0.9 2.5
Tlr2 NM_011905 0.6 4.3
TNFaip3/A20 NM_009397 1.2 10.9
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